News & Events > Events > Qritive Receives Award from ISBP-BCRF for Breast Pathology Research at USCAP 2024   

Qritive Receives Award from ISBP-BCRF for Breast Pathology Research at USCAP 2024   

Singapore, March 24, 2024 – Qritive, a leading digital pathology company, is pleased to announce its achievement in winning first place in the ISBP-BCRF Larry Norton MD Trainee Abstract Award in Breast Pathology in Research Category at the United States and Canadian Academy of Pathology (USCAP) 2024 annual meeting. This recognition highlights Qritive’s commitment to advancing breast pathology research.

USCAP is a premier pathology conference where pathologists from all over the world gather to share research and innovations. Among hundreds of submissions, Qritive’s success underscores the quality of its research in the field.

The winning abstract titled “A Deep Learning Module to Assist Pathologists in Identifying Lymph Node Metastasis in Breast Tumor Resections” demonstrates Qritive’s dedication to leveraging artificial intelligence for improved diagnostic accuracy in breast cancer pathology. This AI-powered product screens breast lymph nodes for the presence of metastasic deposits and provides detailed results to pathologists. Qritive’s validation study demonstrates its capacity to enhance diagnostic precision while significantly expediting the lymph node screening process by histopathologists.

Dr. Sahil Ajit Saraf, Senior Pathologist at Qritive, expressed gratitude for the award, stating, “As a fellow pathologist put it during USCAP 2024 in Baltimore, when it comes to the adoption of AI in pathology, it is not if but when. And I am glad to play a role in this transition. AI will be instrumental in transforming our practice for the greater good of patients and clinicians.”

In addition to this achievement, Qritive is expanding globally, with operations in India, Morocco, UAE, and USA. Qritive provides a comprehensive suite of digital pathology solutions, encompassing a streamlined image management system, specialized and generic AI modules that cater to various cancer types, as well as expert pathologist services tailored to bolster pathology research endeavors.

We have proposed a novel framework for validation of any AI products for pathology where doctors need to spend substantial time to find small anomalies, for example, identifying metastasis in lymph nodes. Our validation framework puts a strong emphasis on the workflow of pathologists when they’re dealing with a needle-in-a-haystack problem, and it provides a structure to measure workflow productivity and diagnostic accuracy improvements.” said Dr Kaveh Taghipour, Chief Technology Officer at Qritive.

About Qritive:

Headquartered in Singapore, with operations in US & India, Qritive is a breakthrough Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis and improving health outcomes with the assistance of AI-based solutions. Qritive expands on deep learning technology to support the interpretation of pathology tests for time and resource-strapped medical imaging professionals – enabling faster diagnosis and reducing time to treatment for patients. Qritive is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.

Our Newsletter

Subscribe to our newsletter to get timely updates on latest news and articles.

Join our team

Join us and build products for cancer diagnosis. We are looking for great people to join our growing team.
Back to top

and modern

Contemporary theme especially made for technology & software developing company websites. Deon, a new age of WP design.